お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
808261

血糖モニタリングの世界市場

Blood Glucose Monitoring Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 223 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
血糖モニタリングの世界市場
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 223 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の血糖モニタリング市場は、2019年から2024年にかけて11.88%のCAGRで推移し、2019年には128億米ドル規模の市場に成長すると予測されています。

当レポートでは、世界の血糖モニタリング市場を調査し、市場の概要、種類・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査結果
  • 前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 種類別
    • 血糖自己測定器
    • 持続血糖測定器
  • エンドユーザー別
    • 病院
    • 個人
  • 地域別
    • 北米
    • 欧州
    • ラテンアメリカ
    • アジア太平洋地域
    • 中東・アフリカ

第6章 市場指標

  • 1型糖尿病の患者の推移と予測
  • 2型糖尿病の患者の推移と予測

第7章 競合情勢

  • 企業プロフィール
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業シェア分析
    • Roche
    • Johnson & Johnson
    • Abboott Diabetes Care
    • その他

第8章 市場機会と将来展望

目次
Product Code: 55927

The blood glucose monitoring market is expected to register a CAGR of 10% during the forecast period of 2020-2025. The market is estimated to reach a value of USD 13.7 billion by 2020.

  • Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices.
  • Obesity is also considered as one of the major factors contributing to the disease, primarily Type 2 diabetes.
  • Also, other factors, such as technological innovations and advancements, give many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose level is established with continuous glucose monitoring devices.
  • These devices help in the early detection of hypo and hyperglycemic conditions.This favor is expected to drive the market for glucose monitoring.

Key Market Trends

Glucometer consumables (test strips and lancets) occupy highest market share

Although CGM is an advanced way for people living with diabetes to check glucose readings in real-time, SMBG is the most preferred device by the patients due to its economic affordability and less sophisticated usage when compared to CGM. The SBGM occupies more than 87% of the share in the blood glucose monitoring market. The further segmented market of SBGM gives an understanding that the disposable consumables - test strips and lancets, occupy the larger market share, compared to glucometer devices. However, the CAGR for glucometer devices is high. CGM, though it provides real-time data of blood glucose levels for patients, has low adaptability in the emerging markets. However, CGM's adaptability is high in developed markets. The cost factor is a major concern for the stunted growth of CGM in emerging markets.

North America is leading the market

In 2019, North America, especially the United States, held the largest share in the blood glucose monitoring market, due to the large patient pool and wide acceptance of advanced technologies followed by Europe, with moderate growth. Asia-Pacific, Latin America, and the Middle East & Africa witnessed low growth, due to economic affordability.

Competitive Landscape

The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. Mergers and acquisitions among the players in the recent past helped the companies to strengthen their market presence. For example, Dexcom partnered with Julphar to increase its presence in the Middle Eastern region.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Self-monitoring blood glucose devices (Value and Volume, 2012-2025)
    • 5.1.1 By Component
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 By End Use
      • 5.1.2.1 Hospital (Value and Volume, 2012-2025)
      • 5.1.2.1.1 Glucometer Devices
      • 5.1.2.1.2 Test Strips
      • 5.1.2.1.3 Lancets
      • 5.1.2.2 Personal (Value and Volume, 2012-2025)
      • 5.1.2.2.1 Glucometer Devices
      • 5.1.2.2.2 Test Strips
      • 5.1.2.2.3 Lancets
  • 5.2 Continuous blood glucose monitoring devices (Value and Volume, 2012-2025)
    • 5.2.1 By Component
      • 5.2.1.1 Sensors
      • 5.2.1.2 Durables (Receivers and Transmitters)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (Value and Volume, 2012-2025)
      • 5.3.1.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.1.1.2 By End User (Hospital and Personal)
      • 5.3.1.1.2 Continuous Glucose Monitoring devices
      • 5.3.1.1.2.1 By Component (Sensors and Receivers)
      • 5.3.1.2 Canada (Value and Volume, 2012-2025)
      • 5.3.1.2.1 Self-monitoring blood glucose devices
      • 5.3.1.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.1.2.1.2 By End User (Hospital and Personal)
      • 5.3.1.2.2 Continuous Glucose Monitoring
      • 5.3.1.2.2.1 By Component (Sensors and Receivers)
      • 5.3.1.3 Rest of North America (Value and Volume, 2012-2025)
      • 5.3.1.3.1 Self-monitoring blood glucose devices
      • 5.3.1.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.1.3.1.2 By End User (Hospital and Personal)
      • 5.3.1.3.2 Continuous Glucose Monitoring
      • 5.3.1.3.2.1 By Component (Sensors and Receivers)
    • 5.3.2 Europe
      • 5.3.2.1 France (Value and Volume, 2012-2025)
      • 5.3.2.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.2.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.1.1.2 By End User (Hospital and Personal)
      • 5.3.2.1.2 Continuous Glucose Monitoring
      • 5.3.2.1.2.1 By Component (Sensors and Receivers)
      • 5.3.2.2 Germany (Value and Volume, 2012-2025)
      • 5.3.2.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.2.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.2.1.2 By End User (Hospital and Personal)
      • 5.3.2.2.2 Continuous Glucose Monitoring
      • 5.3.2.2.2.1 By Component (Sensors and Receivers)
      • 5.3.2.3 Italy (Value and Volume, 2012-2025)
      • 5.3.2.3.1 Self-monitoring blood glucose devices
      • 5.3.2.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.3.1.2 By End User (Hospital and Personal)
      • 5.3.2.3.2 Continuous Glucose Monitoring
      • 5.3.2.3.2.1 By Component (Sensors and Receivers)
      • 5.3.2.4 Spain (Value and Volume, 2012-2025)
      • 5.3.2.4.1 Self-monitoring blood glucose devices
      • 5.3.2.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.4.1.2 By End User (Hospital and Personal)
      • 5.3.2.4.2 Continuous Glucose Monitoring
      • 5.3.2.4.2.1 By Component (Sensors and Receivers)
      • 5.3.2.5 United Kingdom (Value and Volume, 2012-2025)
      • 5.3.2.5.1 Self-monitoring blood glucose devices
      • 5.3.2.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.5.1.2 By End User (Hospital and Personal)
      • 5.3.2.5.2 Continuous Glucose Monitoring
      • 5.3.2.5.2.1 By Component (Sensors and Receivers)
      • 5.3.2.6 Russia (Value and Volume, 2012-2025)
      • 5.3.2.6.1 Self-monitoring blood glucose devices
      • 5.3.2.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.6.1.2 By End User (Hospital and Personal)
      • 5.3.2.6.2 Continuous Glucose Monitoring
      • 5.3.2.6.2.1 By Component (Sensors and Receivers)
      • 5.3.2.7 Rest of Europe (Value and Volume, 2012-2025)
      • 5.3.2.7.1 Self-monitoring blood glucose devices
      • 5.3.2.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.7.1.2 By End User (Hospital and Personal)
      • 5.3.2.7.2 Continuous Glucose Monitoring
      • 5.3.2.7.2.1 By Component (Sensors and Receivers)
    • 5.3.3 Latin America
      • 5.3.3.1 Mexico (Value and Volume, 2012-2025)
      • 5.3.3.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.3.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.3.1.1.2 By End User (Hospital and Personal)
      • 5.3.3.1.2 Continuous Glucose Monitoring
      • 5.3.3.1.2.1 By Component (Sensors and Receivers)
      • 5.3.3.2 Brazil (Value and Volume, 2012-2025)
      • 5.3.3.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.3.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.3.2.1.2 By End User (Hospital and Personal)
      • 5.3.3.2.2 Continuous Glucose Monitoring
      • 5.3.3.2.2.1 By Component (Sensors and Receivers)
      • 5.3.3.3 Rest of Latin America (Value and Volume, 2012-2025)
      • 5.3.3.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.3.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.3.3.1.2 By End User (Hospital and Personal)
      • 5.3.3.3.2 Continuous Glucose Monitoring
      • 5.3.3.3.2.1 By Component (Sensors and Receivers)
    • 5.3.4 Asia-Pacific
      • 5.3.4.1 Japan (Value and Volume, 2012-2025)
      • 5.3.4.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.1.1.2 By End User (Hospital and Personal)
      • 5.3.4.1.2 Continuous Glucose Monitoring
      • 5.3.4.1.2.1 By Component (Sensors and Receivers)
      • 5.3.4.2 South Korea (Value and Volume, 2012-2025)
      • 5.3.4.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.2.1.2 By End User (Hospital and Personal)
      • 5.3.4.2.2 Continuous Glucose Monitoring
      • 5.3.4.2.2.1 By Component (Sensors and Receivers)
      • 5.3.4.3 China (Value and Volume, 2012-2025)
      • 5.3.4.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.3.1.2 By End User (Hospital and Personal)
      • 5.3.4.3.2 Continuous Glucose Monitoring
      • 5.3.4.3.2.1 By Component (Sensors and Receivers)
      • 5.3.4.4 India (Value and Volume, 2012-2025)
      • 5.3.4.4.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.4.1.2 By End User (Hospital and Personal)
      • 5.3.4.4.2 Continuous Glucose Monitoring
      • 5.3.4.4.2.1 By Component (Sensors and Receivers)
      • 5.3.4.5 Australia (Value and Volume, 2012-2025)
      • 5.3.4.5.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.5.1.2 By End User (Hospital and Personal)
      • 5.3.4.5.2 Continuous Glucose Monitoring
      • 5.3.4.5.2.1 By Component (Sensors and Receivers)
      • 5.3.4.6 Vietnam (Value and Volume, 2012-2025)
      • 5.3.4.6.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.6.1.2 By End User (Hospital and Personal)
      • 5.3.4.6.2 Continuous Glucose Monitoring
      • 5.3.4.6.2.1 By Component (Sensors and Receivers)
      • 5.3.4.7 Malaysia (Value and Volume, 2012-2025)
      • 5.3.4.7.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.7.1.2 By End User (Hospital and Personal)
      • 5.3.4.7.2 Continuous Glucose Monitoring
      • 5.3.4.7.2.1 By Component (Sensors and Receivers)
      • 5.3.4.8 Indonesia (Value and Volume, 2012-2025)
      • 5.3.4.8.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.8.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.8.1.2 By End User (Hospital and Personal)
      • 5.3.4.8.2 Continuous Glucose Monitoring
      • 5.3.4.8.2.1 By Component (Sensors and Receivers)
      • 5.3.4.9 Philippines (Value and Volume, 2012-2025)
      • 5.3.4.9.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.9.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.9.1.2 By End User (Hospital and Personal)
      • 5.3.4.9.2 Continuous Glucose Monitoring
      • 5.3.4.9.2.1 By Component (Sensors and Receivers)
      • 5.3.4.10 Thailand (Value and Volume, 2012-2025)
      • 5.3.4.10.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.10.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.10.1.2 By End User (Hospital and Personal)
      • 5.3.4.10.2 Continuous Glucose Monitoring
      • 5.3.4.10.2.1 By Component (Sensors and Receivers)
      • 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)
      • 5.3.4.11.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.11.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.11.1.2 By End User (Hospital and Personal)
      • 5.3.4.11.2 Continuous Glucose Monitoring
      • 5.3.4.11.2.1 By Component (Sensors and Receivers)
    • 5.3.5 Middle-East and Africa
      • 5.3.5.1 Saudi Arabia (Value and Volume, 2012-2025)
      • 5.3.5.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.1.1.2 By End User (Hospital and Personal)
      • 5.3.5.1.2 Continuous Glucose Monitoring
      • 5.3.5.1.2.1 By Component (Sensors and Receivers)
      • 5.3.5.2 Iran (Value and Volume, 2012-2025)
      • 5.3.5.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.2.1.2 By End User (Hospital and Personal)
      • 5.3.5.2.2 Continuous Glucose Monitoring
      • 5.3.5.2.2.1 By Component (Sensors and Receivers)
      • 5.3.5.3 Egypt (Value and Volume, 2012-2025)
      • 5.3.5.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.3.1.2 By End User (Hospital and Personal)
      • 5.3.5.3.2 Continuous Glucose Monitoring
      • 5.3.5.3.2.1 By Component (Sensors and Receivers)
      • 5.3.5.4 Oman (Value and Volume, 2012-2025)
      • 5.3.5.4.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.4.1.2 By End User (Hospital and Personal)
      • 5.3.5.4.2 Continuous Glucose Monitoring
      • 5.3.5.4.2.1 By Component (Sensors and Receivers)
      • 5.3.5.5 South Africa (Value and Volume, 2012-2025)
      • 5.3.5.5.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.5.1.2 By End User (Hospital and Personal)
      • 5.3.5.5.2 Continuous Glucose Monitoring
      • 5.3.5.5.2.1 By Component (Sensors and Receivers)
      • 5.3.5.6 Rest of Middle and Africa (Value and Volume, 2012-2025)
      • 5.3.5.6.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.6.1.2 By End User (Hospital and Personal)
      • 5.3.5.6.2 Continuous Glucose Monitoring
      • 5.3.5.6.2.1 By Component (Sensors and Receivers)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes population (2012-2025)
  • 6.2 Type-2 Diabetes population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche Holding AG
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Dexcom Inc.
    • 7.1.5 Medtronic PLC
    • 7.1.6 Arkray Inc.
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon Laboratories Inc.
    • 7.1.11 Medisana AG
    • 7.1.12 Trivida Functional Medicine
    • 7.1.13 Rossmax International Ltd
  • 7.2 COMPANY SHARE ANALYSIS

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.